The Genentech Foundation is a U.S.-based, private charitable foundation whose donations are made possible by contributions from Genentech. Genentech is committed to being a strong corporate citizen, and the Genentech Foundation is one of the most important ways in which we give back to our communities.
Sean Johnston, Ph.D., J.D., Board Chair, Senior Vice President and
Paul Bezy, Vice President, SSF Drug Substance and Drug Product Operations
Carla Boragno, Vice President, SSF Site Services
Chris Horan, Senior Vice President, Global Product and Supply Chain Management
Sarah Hymowitz, Ph.D., Vice President, Protein Sciences
Heather Jorajuria, Vice President, Global Product Development Quality Assurance
Sara Kenkare-Mitra, Ph.D., Senior Vice President, Development Sciences
Frank Lee, Senior Vice President, Global Product Strategy, Therapeutic Area Head, I2O
Nancy Oaks, Vice President, Hematology Franchise
Eric J. Olson, Vice President, US Product Development Regulatory, Genentech, Inc.
Geoff Teeter, Vice President, Corporate Relations
Sean Johnston started working in Genentech’s legal department in 1987 as an intern and joined the department as a regular employee in 1990. After holding various positions there, in 1998 he was named Vice President, Intellectual Property, and in 2007 he was named Senior Vice President and General Counsel. He manages Genentech’s in-house legal staff of over 100 attorneys and patent agents, who are responsible for Genentech’s intellectual property, corporate law, and litigation matters.
Prior to his employment with Genentech, Sean was law clerk to Judge Wm. Matthew Byrne, Jr. in the U.S. District Court, Central District of California in Los Angeles. Before that, he was a research scientist at International Genetic Engineering, Inc./Xoma Ltd.
Sean received a Bachelor of Science degree in biochemistry from the University of California, Davis and a Ph.D. in molecular biology from the University of California, Los Angeles. He also holds a J.D. with Honors from Stanford Law School.
Paul Bezy is currently the Site Head (VP) for the South San Francisco Drug Substance and Drug Product Operations. Taking advantage of proximity and partnership with PTD/gRED to maximize speed, his organization delivers the gRED large molecule pipeline (DS and DP), and launches significantly accelerated new products. Paul started his career at Genentech as a manufacturing technician, and has held roles of increasing responsibility in PTB and PTD, including head of MSAT. He started the Genentech high throughput pilot plant facilities in SSF, and served as the Technical Development Team leader for the gRED Anti-Abeta program (Crenezumab) from pre-clinical R&D through phase II development. Paul holds a Bachelor Degree in Microbiology from UC Santa Barbara.
Carla Boragno is a transformational business leader known for delivering results, scaling organizations for growth, and building high-performing global teams. Carla is a true change agent, with a passion for motivating and inspiring talent. Carla's expertise across multiple disciplines (including engineering, manufacturing, procurement, IT and M&A integration) and her track record of success over 25+ years makes her a natural choice to lead large-scale, cross-functional organizations and initiatives that require innovative solutions and making good teams great.
In Carla’s current role as Vice President of Site Services she is accountable for Genentech’s corporate real estate portfolio, physical infrastructure, and several key workplace services for the South San Francisco campus. This progressive biotechnology campus consists of approximately 9,000 employees, 180 acres, and over 5 million square feet of space devoted to research and development, manufacturing, marketing and administration.
Prior to her current role, Carla has held numerous leadership positions across functions and geographies. As Head of Procurement Services for Roche’s Global Pharma Procurement organization, she was responsible for strategic and operational procurement services across Roche. While based in Singapore, Carla led the transition and full integration of a newly acquired manufacturing facility into Genentech’s existing Singapore operations. Carla also had responsibility for the implementation of a $1.5B capital design and construction portfolio during peak growth at Genentech.
Carla holds a Bachelor of Science, Chemical Engineering from University of California, Berkeley. Carla is a mentor to many within and outside Genentech, and is sought after as an inspirational speaker. She also serves on the Board of Directors for Northern California Junior Achievement and the Genentech Foundation. Outside of work, she can be found working in her kitchen and garden, and volunteering at her daughter’s school.
Chris Horan is currently Head of Product and Supply Chain Management for Roche Pharma. In this role, Chris is responsible for end to end Technical Product Management, global Planning and Operations, regional Supply Chain (including S&OP), and Supply Chain Capabilities for Pharma Technical Operations. Chris joined Genentech in 2004 and moved to Supply Chain Planning in 2006. In 2009, he was appointed Head of North American Supply Chain and PT Business Process Excellence. From 2011-2013, Chris led the sourcing of all direct materials, contract manufacturing services, and engineering for Roche Pharma.
Prior to joining Genentech, Chris was with Merck & Company, Inc. leading international manufacturing capacity and business process improvement projects for 16 years.
Sarah Hymowitz is currently the Vice President of Protein Sciences. In this role, she leads an organization of 180-people including the Departments of Antibody Engineering, Structural Biology, Protein Chemistry, BioMolecular Resources and Microchemistry, Proteomics and Lipidomics. Collectively, these groups create biological reagents and data that further our understanding of the structure, function, and regulation of proteins of therapeutic interest and contribute to the discovery of large and small molecule therapeutics. Sarah is a member of the Research Leadership Team and contributes to research portfolio decisions as a participant in the Small Molecule Leadership team and as a standing reviewer for the Research Review Committee. She chairs the Proteins Leadership Team, which is responsible for large molecule drug discovery in collaboration with discovery biology groups.
Sarah earned a B.A in Chemistry from Swarthmore College followed by a Ph.D. in Biophysics from the University of California, San Francisco. She joined Genentech as a postdoctoral researcher in 1999 and was subsequently hired as a Scientist in 2002. Throughout her career, Sarah has played leadership roles in basic research, antibody and small molecule drug discovery projects, and has contributed to over 75 scientific publications and patent applications. She is passionate about mentoring and developing talent.
Heather Jorajuria is the current Vice President and Global Head, Product Development Quality Assurance. In this role she is responsible for leading a global team responsible for quality assurance oversight activities, including enterprise risk management, the conduct of compliance audits, and management of Regulatory Authority Inspections across all clinical trial, non-clinical and pharmacovigilance activities for Roche Pharma, including the REDs. Her team provides evidence to Roche Pharma that GLP, GCP and PV regulated activities are compliant in order to protect patient safety and ensure data integrity. Heather began her career in Compliance at Genentech in South San Francisco, CA from 1995 to 2000. She then spent 5 years with Pfizer (Pharmacia/Sugen) as a Quality Assurance Manager and 7 years with Amgen as the Executive Director of Compliance. Heather re-joined Genentech in 2012 in her current role.
Heather has been in the pharmaceutical and biotech industry for over 20 years. She is actively involved in industry initiatives and is currently participating in industry forums such as Linking Leaders, AVOCA, and TransCelerate. Heather sits on the advisory board of TransCelerate for the Quality Management System initiative. Heather obtained her Bachelor of Arts in Kinesiology from the University of Colorado, Boulder. Outside of work she enjoys spending time with her family and cooking gourmet dishes.
Sara Kenkare-Mitra is currently Senior Vice President of Development Sciences, a translational sciences organization that spans R&D at Genentech. In this role she has responsibility for ensuring the successful translation of promising molecule-discoveries from Research into Development through nonclinical PK/PD and safety strategies and for key components of clinical development including ensuring the right dose/exposure of drug candidates and the right proof of activity and patient selection strategies through biomarkers and diagnostics.
Sara has had a significant impact on the development of a number of biologics and small molecules leading to Genentech's key product approvals including Avastin, Tarceva, Lucentis, Xolair, Erivedge, Perjetta and Kadcyla. In addition, more than 60 Investigational New Drug applications with potential to treat a multitude of diseases in particular cancer, have been filed by her organization with US and ex-US regulatory agencies. At Genentech she is a key member of the technical and portfolio decision making committees.
Sara also holds adjunct faculty positions at UCSF in the Department of Bioengineering and Therapeutic Sciences and the University of the Pacific in Stockton. She has a passion for developing therapies to meet significant unmet medical needs with a strong scientific basis and an emphasis on personalized medicine. Sara was elected to the Institute of Medicine, National Academy in 2014. Selected as one of the 150 Most Influential Business women by San Francisco Business times in 2011, one of the 150 top alumni of UCSF in 2015, she has also won awards and recognition at Genentech not only for her excellence in leadership and mentorship, but also for her passionate commitment to the healthcare industry as a whole.
Frank Lee currently serves as Senior Vice President in the GPS organization, where he heads the Immunology, Infectious Diseases and Ophthalmology therapy area. Prior to GPS, Frank was VP of the HER2 Franchise, where he had commercial responsibility for the breast cancer portfolio.
Frank joined Genentech in 2006, and has held positions of increasing responsibility within the US Commercial Organization including Marketing Director, Franchise Head and VP of Oral Oncolytics Sales and Marketing. Before coming to Genentech, Frank was Executive Director in the Ophthalmics Business Unit at Novartis. Prior to Novartis, Frank served in roles of increasing responsibility within sales, marketing, business development, and manufacturing at Johnson & Johnson and Eli Lilly.
Frank earned an MBA from the Wharton Graduate School of Business at the University of Pennsylvania and a Bachelor of Science in Chemical Engineering from Vanderbilt University.
Nancy Oaks serves as Vice President of Sales and Marketing in the Hematology Franchise. Nancy Oaks has been with Genentech for 10 years and is currently leading the Hematology Commercial team in the U.S. As a franchise head Nancy is responsible for all the sales and marketing activities for Rituxan, Gazyva and Venclexta. Nancy is also a board member for the Genentech Foundation.
Prior to her current role, Nancy was the VP for Primary Care and led the Boniva commercial team. She was also the Senior Director - Payer Team within the Managed Care and Customer Operations organization (MCCO). The team's mission is to serve as Genentech's key point of contact for the payer, PBM, employer, as well as Medicare and Medicaid organizations and to proved information and programs to enhance appropriate patient access. Nancy started at Genentech in 2006 as the National Sales Director for Xolair.
Over the last 20 years, Nancy gained experiences in many facets of the bio-tech/pharmaceutical business including finance, marketing, commercial operations and sales. Nancy has served in leadership roles in commercial operations responsible for market research, sales operations, compliance, commercial I.T. and data analysis. She has also led several sales teams primarily in the dermatology and respiratory therapeutic areas. Prior to joining Genentech, Nancy held several commercial leadership positions at Amgen, Stiefel, Allergan, and Novartis.
Nancy is graduate of Pace University in New York City and is a member of the Healthcare Businesswomen Association and McKinsey’s Women Executive Roundtable.
Eric J. Olson is currently the Vice President of US Product Development Regulatory. In this role, Eric manages the policy, intelligence and commercial regulatory affairs (CORA) groups in PDR. He sits on the PDR Leadership Team contributing to the overall direction of the global Regulatory group within the company.
While previously based in Basel, Switzerland he served as business lead for Product Development’s (PD) Smarter Information Management initiative, a multi-year innovation project aimed toward transforming the way PD uses its vast clinical information. Additionally, Eric was the Head of CORA, Director of PD Projects for Genentech’s former President Sue Hellmann and one of the company’s lobbyists in Washington, DC. Eric also serves as the Site Head for Product Development in South San Francisco and on the Board of the Genentech Foundation, a private charitable foundation the company created to give back to its local community.
Prior to joining Genentech, Eric was Chief of Staff to U.S. Representative Anna G. Eshoo - managing all legislative, constituent and administrative functions in her Washington, D.C. office. He has held legislative roles for former U.S. Senate Democratic Leader Thomas Daschle, Rep. Eshoo, and former Rep. Norm Mineta.
Eric graduated from Santa Clara University in 1995 with a B.A. in Political Science and minor in Communication. He lives in Redwood City, CA with his wife and two daughters. Hobbies include playing and coaching sports, reading and learning about wine. He played football at Santa Clara University but after many years and many knee surgeries, he currently prefers non-contact sports such as distance running and triathlon.
Geoffrey P. Teeter is Vice President, Corporate Relations at Genentech. In this role, Geoff leads the company’s communication strategy and oversees the activities of the Corporate Relations department including corporate and product public relations, corporate branding, science communications, internal communications, corporate and employee giving and digital strategy and channels.
Geoff is a member of the global Communication Leadership Team and serves as the North American Communications Lead for the Roche Group in the United States. He is a member of the Board of Directors of both the Genentech Foundation and the Genentech Access to Care Foundation.
During his 24 years with the company, Geoff has developed and implemented a number of communications initiatives and strategies that have helped strengthen Genentech's corporate reputation and supported the company's goal of being a great place to work.
Prior to joining Genentech, Geoff worked on behalf of several pharma and healthcare companies at Burson-Marsteller public relations agency in Manhattan, and as a product communications manager at CIBA-Geigy Pharmaceuticals Division. He holds a bachelor's degree in mass communication from St. Bonaventure University.